Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 257-268

  Athanasakis, Kostas ^a   Petrakis, Ioannis ^b   Ollandezos, Mark ^a   Tsoulas, Christos ^b   Patel, Dipen A ^c   Karampli, Eleftheria ^a   Kyriopoulos, John ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b PFIZER INC   (United States)

^c PHARMERIT INTERNATIONAL   (United States)

Author keywords

Antibacterial agents; Complicated skin and soft tissue infection; Cost analysis; Daptomycin; Greek hospitals; Linezolid; Meticillin resistant Staphylococcus aureus; Teicoplanin; Tigecycline; Vancomycin

Indexed keywords

CLINDAMYCIN; DAPTOMYCIN; LINEZOLID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; TREATMENT OUTCOME;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84977071126     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0044-8     Document Type: Article

References (35)

1. Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377–85.
2. Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50(2):238–45.
3. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(s3):iii35–44.
4. Dryden M. Complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: epidemiology, risk factors, and presentation. Surg Infect (Larchmt). 2008;9(s1):s3–10.
5. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007;57(1):7–13.
6. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(s5):S368–77.
7. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189(4):425–8.
8. White B, Seaton RA. Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist. 2011;4:115–27.
9. Sevinç F, Prins JM, Koopmans RP, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother. 1999;43(4):601–6.
10. Laing RB, Mackenzie AR, Shaw H, Gould IM, Douglas JG. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards. J Antimicrob Chemother. 1998;42(1):107–11.
11. Itani KMF, Merchant S, Lin S-J, Akhras K, Alandete JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control. 2011;39(1):42–9.
12. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis. 2011;53(2):177–84.
13. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2011 [Internet]. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2012. Available from: http://www.ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-surveillance-europe-2011.pdf. Accessed 21 May 2013.
14. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010;10(4):227–39.
15. May AK, Stafford RE, Bulger EM, et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt). 2009;10(5):467–99.
16. Köck R, Becker K, Cookson B, et al. Meticillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41):19688.
17. Vourli S, Vagiakou H, Ganteris G, et al. High rates of community-acquired, Panton-Valentine leukocidin (PVL)-positive methicillin-resistant S. aureus (MRSA) infections in adult outpatients in Greece. Euro Surveill. 2009;14(2). (pii: 19089).
18. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus Aureus infections in adults and children. Clin Infect Dis. 2011;52(3):285–92.
19. Stephens JM, Gao X, Patel DA, Verheggen BG, Shelbaya A, Haider S. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013;5:447–57.
20. Itani KMF, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804–16.
21. Ministerial Decision Υ4α/οικ.13740. Greek Government Gazette No 940/B. 2012 [published Mar 27, 2012]. Available from: www.et.gr. [In Greek]. Accessed 31 Jan 2013.
22. Ministry of Health. Price bulletings. Athens: Ministry of Health; 2013. Available from: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn. Accessed 31 Oct 2013.
23. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus—associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12(11):1715–23.
24. Jacobus C, Lindsell C, Leach S, Fermann G, Kressel A, Rue L. Prevalence and demographics of methicillin resistant Staphylococcus aureus in culturable skin and soft tissue infections in an urban emergency department. BMC Emerg Med. 2007;7:19.
25. WHO-CHOICE 2013. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Country-specific unit costs [Internet]. Geneva: World Health Organization; 2013 [updated 2011 July]. Available from: http://www.who.int/choice/country/country_specific/en/. Accessed 31 Oct 2013.
26. Nathwani D, Eckmann C, Lawson W, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect. 2014;. doi:10.1111/1469-0691.12632 [Epub ahead of print].
27. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(s4):iv7–15.
28. Dellit TH, Owens RC, McGowan JE, et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.
29. Goetghebeur M, Landry PA, Han D, Vicente C. Meticillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol. 2007;18(1):27–34.
30. Nathwani D. Impact of meticillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother. 2003;51(s2):ii37–44.
31. Eckmann C, Lawson W, Nathwani D, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014;44(1):56–64.
32. Logman JFS, Stephens J, Heeg B, et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin. 2010;26(7):1565–78.
33. Seaton RA, Johal S, Coia JE, Reid N, Cooper S, Jones BL. Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur J Clin Microbiol Infect Dis. 2014;33(3):305–11.
34. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies. Pharmacoeconomics. 1997;12(2 Pt 1):121–9.
35. Athanasakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J. Estimating the direct cost of type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med. 2010;27(6):679–84.